— Sage Therapeutics (NASDAQ: SAGE) reported fourth quarter 2019 loss of $3.25 per share vs. expected loss per share of $3.61.
— Total revenue stood at $1.96 million vs. $3.68 million expected.
— Sage expects revenue growth of ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD), will be modest over the next couple of quarters with an increase in the rate of growth of ZULRESSO revenue anticipated in the second half of 2020.
— The company will be having a meeting with the FDA in the first quarter of 2020 to discuss about Zuranolone, the clinical program for the treatment of major depressive disorder (MDD) and PPD.
— R&D expenses were $91.3 million compared to $88.8 million in the prior-year quarter. SG&A expenses were $85.1 million vs. $75.7 million in the fourth quarter of 2018.
— SAGE stock, which ended down 1.24% at $63.65, had dropped 12% so far this year.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
Colgate-Palmolive (CL) Q3 2024 Earnings: Key financials and quarterly highlights
Colgate-Palmolive Company (NYSE: CL) reported its third quarter 2024 earnings results today. Net sales increased 2.4% year-over-year to $5 billion. Organic sales grew 6.8%. Net income attributable to Colgate-Palmolive Company was $737
Key takeaways from Southwest Airlines’ (LUV) Q3 2024 earnings report
Shares of Southwest Airlines Co. (NYSE: LUV) were down over 4% on Thursday. The stock has gained 4% over the past three months. The airline reported its earnings results for
HOG Earnings: A snapshot of Harley-Davidson’s Q3 2024 results
Motorcycle manufacturer Harley-Davidson (NYSE: HOG) Thursday reported a sharp fall in sales and net profit for the third quarter of 2024 amid weak demand. Consolidated net income declined to $119
